Other substances

Elvitegravir

An HIV-1 integrase inhibitor and antibiotic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Elvitegravir is a quinolone antibiotic derivate used as a human immunodeficiency virus 1 integrase inhibitor (NCIt).

Elvitegravir on DrugBank
Elvitegravir on PubChem
Elvitegravir on Wikipedia

Synonyms

Vitekta

Marketed as

In combination with other drugs - GENVOYA (COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE); STRIBILD (COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE)

CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis	in silico	4.24	Predicted to impede SARS-CoV-2 RNA-dependent RNA polymerase activity.	Jul/23/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04890626	Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19	Recruiting	Phase 3	Apr/04/2020	Nov/30/2022
Alternative id - PanCOVID Interventions - Drug: Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]\|Drug: Baricitinib + dexamethasone\|Drug: Dexamethasone Study type - Interventional Study results - No Results Available Locations - Hospital Universitario La Paz, Madrid, Spain Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 2193 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mortality
NCT04334928	Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel	Completed	Phase 3	Apr/15/2020	Jul/11/2021
Alternative id - PrEP COVID-19 Interventions - Drug: Emtricitabine/tenofovir disoproxil\|Drug: Hydroxychloroquine\|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo\|Drug: Placebo: Hydroxychloroquine Study type - Interventional Study results - No Results Available Locations - Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain\|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain\|Hospital General de Elche, Elche, Alicante, Spain\|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain\|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain\|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain\|Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain\|Hospital Infanta Margarita, Cabra, Córdoba, Spain\|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain\|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain\|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain\|Hospital San Pedro, Logroño, La Rioja, Spain\|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain\|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain\|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain\|Hospital de Getafe, Getafe, Madrid, Spain\|Hospital Severo Ochoa, Leganés, Madrid, Spain\|Hospital de Móstoles, Móstoles, Madrid, Spain\|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain\|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain\|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain\|Hospital Infanta Elena, Valdemoro, Madrid, Spain\|Hospital Virgen del Castillo, Yecla, Murcia, Spain\|Hospital Costa del Sol, Marbella, Málaga, Spain\|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain\|Hospital Reina Sofía, Tudela, Navarra, Spain\|Hospital Arnau de Vilanova, Llíria, Valencia, Spain\|Hospital de Araba, Alava, Vitoria, Spain\|Hospital General Universitario de Albacete, Albacete, Spain\|Centro Médico Teknon, Barcelona, Spain\|Hospital Clinic, Barcelona, Spain\|Hospital del Mar, Barcelona, Spain\|Hospital Dexeus, Barcelona, Spain\|Hospital Quirón Barcelona, Barcelona, Spain\|Hospital Universitario Sagrat Cor, Barcelona, Spain\|Hospital Universitario de Burgos, Burgos, Spain\|Hospital Virgen de la Luz, Cuenca, Spain\|Hospital Clínico San Cecilio, Granada, Spain\|Hospital Universitario de León, León, Spain\|Hospital Universitario Ramón y Cajal, Madrid, Spain\|Fundación Jiménez Díaz, Madrid, Spain\|Hospital Clinico San Carlos, Madrid, Spain\|Hospital Infanta Leonor, Madrid, Spain\|Hospital La Princesa, Madrid, Spain\|Hospital Universitario 12 de Octubre, Madrid, Spain\|Hospital Universitario Gregorio Marañon, Madrid, Spain\|Hospital Universitario La Paz, Madrid, Spain\|Hospital Universitario Puerta de Hierro, Madrid, Spain\|Hospital Reina Sofía, Murcia, Spain\|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain\|Hospital Virgen de la Victoria, Málaga, Spain\|Complejo Asistencial de Palencia, Palencia, Spain\|Hospital Universitario de Salamanca, Salamanca, Spain\|Hospital General de Segovia, Segovia, Spain\|Hospital Virgen del Rocio, Sevilla, Spain\|Hospital Virgen Macarena, Sevilla, Spain\|Hospital Clinico Universitario, Valencia, Spain\|Hospital Dr. Peset, Valencia, Spain\|Hospital General de Valencia, Valencia, Spain\|Hospital La Fe, Valencia, Spain\|Hospital de Valladolid, Valladolid, Spain\|Hospital Rio Hortega, Valladolid, Spain\|Hospital Lozano Blesa, Zaragoza, Spain\|Hospital Miguel Servet, Zaragoza, Spain\|Hospital Nuestra Señora de Sonsoles, Ávila, Spain Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Prevention Enrollment - 1002 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)\|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)\|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days
NCT04712357	Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19	Recruiting	Not Applicable	Nov/09/2020	Jan/01/2023
Alternative id - CAAE: 34182620.0.0000.5045 Interventions - Drug: Vitamin C 500 MG Oral Tablet\|Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet\|Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet Study type - Interventional Study results - No Results Available Locations - Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 219 Age - 18 Years and older (Adult, Older Adult) Outcome measures - The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.\|SARS-CoV-2 RNA viral load measurements change.\|Proportion of patients with qualitative serum IgM / IgG.\|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.
NCT04359095	Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia	Completed	Phase 2\|Phase 3	Aug/18/2020	Jun/30/2021
Alternative id - 76968 Interventions - Drug: Emtricitabine/tenofovir\|Drug: Colchicine Pill\|Drug: Rosuvastatin\|Other: Standard treatment Study type - Interventional Study results - No Results Available Locations - Clinica santa Maria del lago, Bogota, DC, Colombia\|Clínica Reina Sofía, Bogotá, Colombia\|Fundacion Cardio Infantil, Bogotá, Colombia\|Hospital Universitario San Ignacio, Bogotá, Colombia\|Clinica Universitaria Colombia, Bogotá, Colombia\|Hospital Universitario Nacional de Colombia, Bogotá, Colombia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 650 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mortality\|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection\|Time to death\|Number of Participants that are transferred to the Intensive Care Unit (ICU)\|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.\|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray\|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection
NCT04685512	Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home	Completed	Phase 2\|Phase 3	Nov/18/2020	May/01/2021
Alternative id - 20-070 Interventions - Drug: tenofovir disoproxil and emtricitabine Study type - Interventional Study results - No Results Available Locations - Caen University Hospital, Caen, Calvados, France\|Regional Hospital, Orléans, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA)\|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28\|Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]\|Phase 3: Symptoms score\|Phase 3: Proportion of secondary hospitalization\|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28
NCT04519125	Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia	Not yet recruiting	Phase 2\|Phase 3	Aug/30/2020	Apr/01/2021
Alternative id - 2020 /143\|77389 Interventions - Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)\|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 950 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - SARS-CoV-2 infection\|Serious and non-serious adverse events\|Discontinuation of using TDF/FTC for any reason\|Adherence to TDF/FTC\|Severity of SARS-CoV-2 infection
NCT04405271	TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)	Not yet recruiting	Phase 3	Jul/31/2020	Nov/15/2020
Alternative id - 5616 Interventions - Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 1378 Age - 18 Years and older (Adult, Older Adult) Outcome measures - COVID-19 incident cases\|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology\|Severity of symptomatic COVID-19\|Respiratory symptom duration in days\|Relation between treatments and symptoms duration\|Time course of specific IgM/IgG seroconversion

Export (.csv)